Bain Capital Public Equity Management Ii, LLC Biocryst Pharmaceuticals Inc Call Options Transaction History

Bain Capital Public Equity Management Ii, LLC

$1.99 Billion
Q3 2024

Call Options

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $2.81 Million - $3.49 Million	197,500 Added 7900.0%	200,000 $2.87 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $23,750 - $43,099	2,500 New	2,500 $388,000

Others Institutions Holding BCRX

# of Institutions

279

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

Vanguard Group Inc Valley Forge, PA

20.3M
Shares

$154 Million
0.0% of portfolio
Black Rock Inc. New York, NY

20M
Shares

$152 Million
0.0% of portfolio
Avoro Capital Advisors LLC New York, NY

11.9M
Shares

$90.2 Million
1.36% of portfolio
Kynam Capital Management, LP Princeton, NJ

9.09M
Shares

$69 Million
5.66% of portfolio
State Street Corp Boston, MA

8.85M
Shares

$67.3 Million
0.0% of portfolio

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bain Capital Public Equity Management Ii, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bain Capital Public Equity Management Ii, LLC with notifications on news.

Account